That's up from 4,300 in October 2023 and 4,800 in February. During that month, these centers handled 40% of the prescription volume on average at supported pharmacies, which translates to roughly 16 million prescriptions filled per month at the different sites, the company said. "Right now, they're the backbone to really help us offset some of the workload in our stores, to obviously allow more time for our pharmacists and technicians to spend time with patients," Rick Gates, Walgreens' chief pharmacy offic ...

Core Insights - Walgreens is focusing on automation to enhance efficiency and improve patient interaction as it navigates challenges in the drugstore industry [1][2][5] Group 1: Automation and Micro-Fulfillment Centers - Walgreens is expanding its micro-fulfillment centers, which utilize robots to fill prescriptions, aiming to serve over 5,000 stores by year-end, up from 4,800 in February 2023 [4] - The micro-fulfillment centers currently handle an average of 40% of prescription volume at supported pharmacies, equating to approximately 16 million prescriptions filled monthly [4][7] - The investment in robotic pharmacy fills has generated around $500 million in savings by reducing excess inventory and increasing efficiency [7] Group 2: Operational Changes and Market Position - The company is transitioning from opening new stores to closing underperforming locations to improve profitability amid competition from CVS Health, Amazon, and others [5][6] - Walgreens aims to alleviate the workload of pharmacy staff, allowing them to focus more on clinical services like vaccinations and testing [2][8] - The automation strategy provides Walgreens with a competitive edge over independent pharmacies and some rivals that lack centralized support [9] Group 3: Industry Context and Challenges - The drugstore industry is facing challenges such as declining pharmacy reimbursement rates, reduced consumer spending, and increased competition from online retailers [5][6] - The shift towards automation is partly a response to staff burnout and chronic understaffing issues highlighted by nationwide walkouts in 2023 [6] - While micro-fulfillment centers offer cost savings and efficiency, they also come with risks related to reliance on advanced robotics [10]

Group 1 - Walgreens Boots Alliance (WBA) closed at $11.16, with a +0.95% change from the previous day, outperforming the S&P 500's gain of 0.58% [1] - The stock has increased by 2.5% over the past month, which is below the Retail-Wholesale sector's gain of 10.56% and the S&P 500's gain of 11.33% [1] Group 2 - Analysts expect Walgreens Boots Alliance to report earnings of $0.34 per share, reflecting a year-over-year decline of 46.03%, with projected revenue of $36.66 billion, a 0.85% increase from the same quarter last year [2] - For the full year, earnings are expected to be $1.66 per share and revenue at $151.49 billion, indicating changes of -42.36% and +2.59% respectively from the previous year [3] Group 3 - Recent revisions to analyst forecasts for Walgreens Boots Alliance are important as they reflect near-term business trends, with positive revisions indicating analyst optimism about the company's profitability [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 stocks have returned an average annual gain of +25% since 1988, with Walgreens Boots Alliance currently holding a Zacks Rank of 3 (Hold) [6] Group 4 - Walgreens Boots Alliance is trading at a Forward P/E ratio of 6.65, which is a premium compared to the industry's average Forward P/E of 5.11, and has a PEG ratio of 1.33, compared to the industry average of 0.77 [7] Group 5 - The Retail - Pharmacies and Drug Stores industry, part of the Retail-Wholesale sector, has a Zacks Industry Rank of 4, placing it in the top 2% of over 250 industries, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Walgreens Boots Alliance (WBA) shares have increased by approximately 2.5% since the last earnings report, which is underperforming compared to the S&P 500 [1] Group 1: Earnings Report Insights - The consensus estimate for Walgreens has shifted by 7.08% over the past month, indicating a flatlining of estimates revisions [2] Group 2: VGM Scores - Walgreens has a poor Growth Score of F, while its Momentum Score is rated B, and it has a Value Score of B, placing it in the top 40% for this investment strategy [3] - The overall aggregate VGM Score for Walgreens is D, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - Walgreens holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return from the stock in the upcoming months [4]

Core Insights - The article identifies the worst-performing stocks in May, highlighting the importance for traders to avoid potential downfalls [1] Group 1: Underperforming Stocks - Marriott International Inc (NASDAQ:MAR) has historically averaged a 2.6% loss in May, with only one gain in the last decade [2][3] - Walgreens Boots Alliance Inc (NASDAQ:WBA) has an average loss of 3.9% for May, with only two positive months out of ten [2][3] - The list includes 25 S&P 500 stocks that have underperformed in May over the past ten years [1] Group 2: Performance Data - MAR's average return in May is -1.62% with a median return of -2.57%, and it has a 10% chance of a positive return [3] - WBA's average return is -3.99% with a median return of -2.37%, showing a 20% chance of a positive return [3] - Other notable underperformers include APA (average return -4.98%), TSN (average return -3.59%), and DIS (average return -3.07%) [3] Group 3: Recent Stock Performance - MAR is currently trading at $248.70, down 0.3%, and has seen a 10.9% decline year-to-date [5] - WBA is trading flat at $10.97, with a significant year-over-year decline of 38.4% [6] - Both companies have shown disappointing post-earnings reactions, with MAR finishing lower in six of the last eight sessions following earnings reports [5]

Core Insights - Palantir is leveraging digital twins to unify fragmented data sources for major retailers like Wendy's and Walgreens, enhancing real-time visibility and AI-driven decision-making [1][2] - Wendy's significantly reduced its manual workload using Palantir's AI platform, resolving a syrup shortage across 6,450 restaurants in just five minutes, compared to a full day previously [1][13] - Walgreens improved task efficiency by 30% through intelligent workload routing, scaling from a pilot program in 10 stores to 4,000 stores within eight months [2][19] Group 1: Palantir's Technology and Implementation - Palantir's approach involves creating digital twins, which are virtual models of a client's entire operation, allowing for unified data presentation on a dashboard [3] - The company applies learnings from government data integration to commercial enterprises, focusing on personalization and automation to enhance customer experience and operational efficiency [4][5] - The digital twin for Wendy's monitors the supply chain in real-time, connecting 3,500 trucks and 60 core partners, enabling proactive management of supply issues [9][10] Group 2: Wendy's Case Study - Wendy's historically relied on a stockpiling inventory model, holding $370 million in inventory to meet customer demands, which became unsustainable due to rising costs [7] - The digital twin identified a syrup shortage and recommended immediate actions, allowing Wendy's to manage the issue in five minutes instead of a day [10][12] - The system's analysis revealed a network-wide shortage of 10,200 cases of syrup, enabling Wendy's to order the necessary 3,500 cases from available distribution points [12][13] Group 3: Walgreens Case Study - Walgreens operates 8,500 stores and employs 220,000 workers, collecting billions of data points daily, which were previously housed in disconnected systems [14][15] - Palantir built a digital twin for Walgreens in under 45 days, facilitating real-time insights and dynamic decision-making [16] - The implementation of intelligent routing for pharmacy tasks allowed Walgreens to balance workloads effectively, cutting task time by 30% [17][19]

"Pharmacies have a legal responsibility to prescribe controlled substances in a safe and professional manner, not dispense dangerous drugs just for profit," Attorney General Pamela Bondi said in a statement. "This Department of Justice is committed to ending the opioid crisis and holding bad actors accountable for their failure to protect patients from addiction." WALGREENS SUED BY DOJ, ALLEGING IT KNOWINGLY FILLED ILLEGAL PRESCRIPTIONS INCLUDING 'DANGEROUS' OPIOIDS Walgreens has agreed to pay up to $350 mi ...

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

Company Overview - Walgreens Boots Alliance, Inc. (WBA) is currently positioned as an intriguing investment choice due to solid earnings estimate revision activity [1][3] - The company has seen a positive trend in earnings estimates, with current quarter estimates rising from $0.31 per share to $0.35 per share and current year estimates increasing from $1.60 per share to $1.65 per share over the past 60 days [4] Industry Context - The Retail-Wholesale space, where Walgreens operates, has a Zacks Industry Rank of 4 out of 247 industries, indicating a strong position compared to other segments [2] - The positive performance of Walgreens is supported by broader trends in the Retail-Wholesale industry, suggesting that a rising tide may benefit multiple companies within this sector [2] Investment Potential - Walgreens Boots Alliance is currently rated with a Zacks Rank 3 (Hold), which is considered a favorable signal for potential investors [4] - The combination of a strong industry ranking and solid estimate revisions makes Walgreens Boots Alliance a compelling option for investors seeking opportunities in this segment [5]

Group 1 - CVS Health is highlighted as facing significant issues compared to Walgreens Boots Alliance, indicating a competitive landscape in the pharmacy sector [1] - The article emphasizes the importance of identifying undervalued companies with potential for long-term growth and dividend income [1] - The author expresses a focus on value dividend investing, aiming for substantial compounding returns over time [1] Group 2 - The article does not provide specific financial data or performance metrics for CVS Health or Walgreens Boots Alliance [2] - There is no recommendation or advice given regarding investment suitability for individual investors [2] - The views expressed in the article may not represent the opinions of the broader platform, Seeking Alpha [2]